CLINICAL STUDIES

Psoriatic Arthritis Study

A Phase 3, randomized, double-blind study comparing Upadacitinib (ABT-494) to placebo and to Adalimumab in subjects with active Psoriatic Arthritis who have a history of Inadequate Response to atleast one Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Study Phase:

Phase 3

Criteria:

  • Male or Female of age 18 years or older
  • Diagnosed with active plague psoriasis
  • Inadequate response to DMARDs
  • Diagnosed with PsA
Register